PL4032979T3 - Mutant polipeptydu czynnika ix, jego zastosowania i sposób jego otrzymywania - Google Patents

Mutant polipeptydu czynnika ix, jego zastosowania i sposób jego otrzymywania

Info

Publication number
PL4032979T3
PL4032979T3 PL21200005.3T PL21200005T PL4032979T3 PL 4032979 T3 PL4032979 T3 PL 4032979T3 PL 21200005 T PL21200005 T PL 21200005T PL 4032979 T3 PL4032979 T3 PL 4032979T3
Authority
PL
Poland
Prior art keywords
factor
obtaining
polypeptide mutant
mutant
polypeptide
Prior art date
Application number
PL21200005.3T
Other languages
English (en)
Inventor
Paolo Simioni
Original Assignee
Uniqure Biopharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4032979(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ITBO2008A000564A external-priority patent/IT1394177B1/it
Priority claimed from ITBO2009A000275A external-priority patent/IT1395980B1/it
Application filed by Uniqure Biopharma B.V. filed Critical Uniqure Biopharma B.V.
Publication of PL4032979T3 publication Critical patent/PL4032979T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL21200005.3T 2008-09-15 2009-09-15 Mutant polipeptydu czynnika ix, jego zastosowania i sposób jego otrzymywania PL4032979T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITBO2008A000564A IT1394177B1 (it) 2008-09-15 2008-09-15 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
ITBO2009A000275A IT1395980B1 (it) 2009-05-06 2009-05-06 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione

Publications (1)

Publication Number Publication Date
PL4032979T3 true PL4032979T3 (pl) 2024-09-30

Family

ID=41397565

Family Applications (3)

Application Number Title Priority Date Filing Date
PL19174517.3T PL3581650T3 (pl) 2008-09-15 2009-09-15 Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego wytwarzania
PL09748260T PL2337849T3 (pl) 2008-09-15 2009-09-15 Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego otrzymywania
PL21200005.3T PL4032979T3 (pl) 2008-09-15 2009-09-15 Mutant polipeptydu czynnika ix, jego zastosowania i sposób jego otrzymywania

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL19174517.3T PL3581650T3 (pl) 2008-09-15 2009-09-15 Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego wytwarzania
PL09748260T PL2337849T3 (pl) 2008-09-15 2009-09-15 Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego otrzymywania

Country Status (19)

Country Link
US (13) USRE50288E1 (pl)
EP (5) EP3252157A1 (pl)
CA (1) CA2737094C (pl)
CY (2) CY1125885T1 (pl)
DK (2) DK3581650T3 (pl)
ES (3) ES2687038T3 (pl)
FI (5) FI3581650T3 (pl)
FR (4) FR23C1028I1 (pl)
HK (1) HK1244507A1 (pl)
HR (2) HRP20230259T1 (pl)
HU (6) HUE067487T2 (pl)
LT (5) LT3581650T (pl)
NO (2) NO2023029I1 (pl)
PL (3) PL3581650T3 (pl)
PT (1) PT3581650T (pl)
SI (1) SI3581650T1 (pl)
SM (2) SMT201800468T1 (pl)
TR (1) TR201813067T4 (pl)
WO (1) WO2010029178A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3581650T3 (da) 2008-09-15 2023-03-13 Uniqure Biopharma B V Faktor ix polypeptidmutant, anvendelse deraf og en fremgangsmåde til fremstilling deraf
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
NZ703148A (en) 2012-07-25 2016-08-26 Catalyst Biosciences Inc Modified factor x polypeptides and uses thereof
RS64664B1 (sr) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
SG10202100131WA (en) 2015-06-23 2021-02-25 Childrens Hospital Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
HRP20221089T1 (hr) 2016-02-01 2022-11-25 Bioverativ Therapeutics Inc. Optimizirani geni faktora viii
KR102604510B1 (ko) 2016-07-26 2023-11-23 바이오마린 파머수티컬 인크. 신규 아데노-관련 바이러스 캡시드 단백질
CN116355883A (zh) * 2016-10-14 2023-06-30 四川至善唯新生物科技有限公司 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用
CA3064730A1 (en) 2017-05-22 2018-11-29 Baxalta Incorporated Viral vectors encoding recombinant fix variants with increased expression for gene therapy of hemophilia b
AU2018299865A1 (en) 2017-07-10 2020-01-30 Uniqure Ip B.V. Means and methods for AAV gene therapy in humans
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US11739345B2 (en) 2018-05-09 2023-08-29 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
MX2020012167A (es) 2018-05-14 2022-07-13 Biomarin Pharm Inc Expresion estable de vectores de aav en sujetos juveniles.
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
CA3109579A1 (en) * 2018-08-20 2020-02-27 Ucl Business Ltd Factor ix encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) * 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
AU2019360270B2 (en) 2018-10-18 2025-08-07 Intellia Therapeutics, Inc. Compositions and methods for expressing factor IX.
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
EP4171657A1 (en) 2020-06-24 2023-05-03 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
US20240293516A1 (en) * 2021-07-01 2024-09-05 CSL Behring Lengnau AG Factor ix subcutaneous administration with enhanced safety
WO2025022005A1 (en) * 2023-07-26 2025-01-30 Le Quellec Sandra Intranasal administration of factor ix polypeptides

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316558A1 (en) 1982-08-04 1989-05-24 Btg International Limited Factor IX DNA
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
US6227618B1 (en) 1996-02-23 2001-05-08 Schukra Usa, Inc. Cable attachment for a lumbar support
ATE277172T1 (de) 1996-06-11 2004-10-15 Roche Diagnostics Gmbh Rekombinante blutgerinnungsproteasen
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
ES2340008T3 (es) 1997-02-14 2010-05-27 American Red Cross Expresion de factor ix humano activo en tejido mamario de animales transgenicos.
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6610906B1 (en) 1999-06-09 2003-08-26 The Regents Of The University Of Michigan Nucleotide sequences for gene regulation and methods of use thereof
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
AU2001269961A1 (en) 2000-07-06 2002-01-21 Guilford Pharmaceuticals Improved polymers and polymerization processes
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
BR0212035A (pt) 2001-09-04 2004-08-03 Merck Patent Gmbh Fator ix modificado
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20040009151A1 (en) 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
US20060292117A1 (en) 2002-04-17 2006-12-28 Loiler Scott A Improved rAAv vectors
CN104630192A (zh) 2002-10-02 2015-05-20 催化剂生物科学有限公司 制备与筛选改变特异性蛋白酶的方法
PL2277996T3 (pl) 2003-05-21 2015-03-31 Genzyme Corp Sposoby wytwarzania preparatów rekombinowanych wirionów AAV zasadniczo niezawierających pustych kapsydów
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
DK1781782T3 (da) 2004-08-17 2010-08-23 Csl Behring Gmbh Modificerede vitamin K-afhængige polypeptider
EP1627771B1 (de) 2004-08-19 2008-10-15 Gerd Bär Hubladebühne mit querverschiebbarem Verbindungsrohr
WO2006031226A1 (en) 2004-09-13 2006-03-23 Saint Louis University Region of factor ixa protease domain that interacts with factor viiia and methods therefor
ES2436741T3 (es) 2004-09-22 2014-01-07 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
ES2385837T3 (es) 2004-12-15 2012-08-01 The University Of North Carolina At Chapel Hill Vectores quiméricos
EP2428218A1 (en) 2005-10-21 2012-03-14 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
WO2007059473A2 (en) 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
EP1791039A1 (fr) 2005-11-25 2007-05-30 The Swatch Group Research and Development Ltd. Spiral en verre athermique pour mouvement d'horlogerie et son procédé de fabrication
SI1969127T2 (sl) 2005-12-21 2017-10-30 Cnj Holdings, Inc Metoda pridobivanja biološko aktivnih proteinov, odvisnih od vitamina K, z rekombinantnimi metodami
WO2007089632A2 (en) 2006-01-27 2007-08-09 The University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
WO2007101681A1 (en) 2006-03-07 2007-09-13 Baxter International Inc Highly phosphorylated and sulfated recombinant factor ix
US20080003202A1 (en) 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
EP2009990B1 (en) 2006-04-07 2016-09-21 The Board of Regents of The University of Texas System Methods and compositions related to adenoassociated virus-phage particles
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
US20070280906A1 (en) 2006-06-03 2007-12-06 Ognjen Petras Method to generate mirrored adenoassociated viral vectors
US8383388B2 (en) 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
EP2037892B1 (en) 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
CA2674879A1 (en) 2007-02-01 2008-08-07 Baxter International Inc. Improved fix-mutant proteins for hemophilia b treatment
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
WO2008127654A2 (en) 2007-04-11 2008-10-23 The University Of North Carolina At Chapel Hill Methods and compositions for intra-articular coagulation proteins
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
BRPI0705943A2 (pt) 2007-04-19 2008-12-09 Nautilus Biotech formulaÇÕes de dosagem oral de polipeptÍdeos resistentes À protease e usos das mesmas para tratamento
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20110154516A1 (en) 2007-10-15 2011-06-23 Stafford Darrel W Human factor ix variants with an extended half life
CA2721362A1 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
KR20110005862A (ko) * 2008-04-16 2011-01-19 바이엘 헬스케어 엘엘씨 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도
WO2009130198A2 (en) 2008-04-21 2009-10-29 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
DK3581650T3 (da) 2008-09-15 2023-03-13 Uniqure Biopharma B V Faktor ix polypeptidmutant, anvendelse deraf og en fremgangsmåde til fremstilling deraf
CA2764758C (en) 2009-06-25 2019-02-12 The University Of North Carolina At Chapel Hill Chimeric factor vii molecules
PE20121643A1 (es) 2009-07-31 2012-11-25 Bayer Healthcare Llc Polipeptidos del factor ix modificados y usos de los mismos
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
EP3513802B1 (en) 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
EP3270944B1 (en) 2015-03-17 2019-10-23 Vrije Universiteit Brussel Optimized liver-specific expression systems for fviii and fix
CN108093639B (zh) 2015-04-16 2022-07-19 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
SG10202100131WA (en) 2015-06-23 2021-02-25 Childrens Hospital Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
WO2017180861A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsulvania Gene therapy for treating hemophilia b
EP3452102B9 (en) 2016-04-15 2024-09-04 The Trustees of The University of Pennsylvania Gene therapy for treating hemophilia a
AU2018299865A1 (en) 2017-07-10 2020-01-30 Uniqure Ip B.V. Means and methods for AAV gene therapy in humans
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Also Published As

Publication number Publication date
US9982248B2 (en) 2018-05-29
WO2010029178A1 (en) 2010-03-18
EP4032979B1 (en) 2024-05-01
PT3581650T (pt) 2023-03-08
US10465180B2 (en) 2019-11-05
US20200190498A1 (en) 2020-06-18
EP4032979A1 (en) 2022-07-27
EP2337849A1 (en) 2011-06-29
SMT201800468T1 (it) 2018-11-09
FIC20230026I1 (fi) 2023-07-25
USRE50288E1 (en) 2025-02-04
CY1125885T1 (el) 2024-02-16
US20210214704A1 (en) 2021-07-15
ES2940323T3 (es) 2023-05-05
PL2337849T3 (pl) 2018-11-30
HUS2500006I1 (hu) 2025-02-28
FR24C1041I1 (fr) 2024-12-06
FIC20240036I1 (fi) 2024-10-29
CA2737094F (en) 2010-03-18
TR201813067T4 (tr) 2018-09-21
FIC20240037I1 (fi) 2024-10-30
PL3581650T3 (pl) 2023-05-22
EP3581650A2 (en) 2019-12-18
EP4219547A2 (en) 2023-08-02
HUS2400037I1 (hu) 2024-11-28
US9249405B2 (en) 2016-02-02
US20220002702A1 (en) 2022-01-06
US20250179462A1 (en) 2025-06-05
EP3581650B1 (en) 2022-12-28
HK1244507A1 (en) 2018-08-10
CA2737094A1 (en) 2010-03-18
EP2337849B1 (en) 2018-06-13
FR23C1028I1 (fr) 2023-10-06
US20200199564A1 (en) 2020-06-25
EP3581650A3 (en) 2020-03-25
US20110244550A1 (en) 2011-10-06
FR24C1040I1 (fr) 2024-12-06
EP4032979C0 (en) 2024-05-01
HRP20181442T1 (hr) 2018-12-14
FIC20250007I1 (fi) 2025-01-22
FR25C1004I1 (fr) 2025-02-28
SI3581650T1 (sl) 2023-06-30
NO2023029I1 (no) 2023-07-31
CA2737094C (en) 2018-02-20
LTPA2024530I1 (pl) 2024-11-25
EP4219547A3 (en) 2023-10-18
HUE067487T2 (hu) 2024-10-28
US20180258413A1 (en) 2018-09-13
US20170355973A1 (en) 2017-12-14
FI3581650T3 (fi) 2023-03-23
NO2025007I1 (no) 2025-01-21
LT3581650T (lt) 2023-05-10
HUS2300024I1 (hu) 2023-08-28
US20210238573A1 (en) 2021-08-05
LTPA2023521I1 (pl) 2023-08-25
DK3581650T3 (da) 2023-03-13
HUS2400036I1 (hu) 2024-11-28
EP3252157A1 (en) 2017-12-06
LTPA2024529I1 (pl) 2024-12-10
HUE061345T2 (hu) 2023-06-28
DK2337849T3 (en) 2018-10-01
US20160122740A1 (en) 2016-05-05
LTPA2025503I1 (pl) 2025-02-10
SMT202300084T1 (it) 2023-05-12
ES2687038T3 (es) 2018-10-23
ES2985035T3 (es) 2024-11-04
US20200231958A1 (en) 2020-07-23
CY2023016I2 (el) 2024-02-16
CY2023016I1 (el) 2024-02-16
US20220090042A1 (en) 2022-03-24
HRP20230259T1 (hr) 2023-04-28

Similar Documents

Publication Publication Date Title
PL4032979T3 (pl) Mutant polipeptydu czynnika ix, jego zastosowania i sposób jego otrzymywania
PL2358756T3 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
EP2253009A4 (en) LOW TEMPERATURE PLASMA PROBE AND METHODS OF USE
BRPI0919575A2 (pt) método, e, composição
PL2640052T3 (pl) Terminal i sposób wyboru trybu kodowania
BRPI1007175A2 (pt) Polipeptídeos hidroxifenilpriruvato dioxigenase mutantes e métodos de uso
LT3205334T (lt) Būdas ir kompozicija, skirti akių hipertenzijai ir glaukomai gydyti
BRPI0920284A2 (pt) composição e método
BRPI0913227A2 (pt) método, e objeto
BRPI0823277A2 (pt) Composição, e , método
DK3121280T3 (da) Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
EP2288365A4 (en) TARGETED COOLING FACTORS AND METHOD OF APPLICATION THEREFOR
BRPI1006996A2 (pt) composição, método e uso
ITBO20080047A1 (it) Azionamento elettrico e metodo di pilotaggio dello stesso.
EP2281932A4 (en) ARAMID CABLE AND METHOD FOR MANUFACTURING THE SAME
BRPI0823238A2 (pt) Composição, e, método
EP2340297A4 (en) COMPOSITION, ITS MANUFACTURING METHOD AND USE
FI20085694A0 (fi) Menetelmä induktiivisen sähkökomponentin valmistamiseksi, induktiivinen sähkökomponentti ja sen käyttö
DE112009001910A5 (de) Sleep determination and sleep determination method
IT1397996B1 (it) Endoreattore e metodo di controllo della combustione nell'endoreattore stesso.
ZA201100019B (en) Variant hhip1 protein and methods and uses thereof
AP2011005797A0 (en) Building components and method of manufacturing the same.
BRPI0822856A2 (pt) Composição, e, método
FI20085267L (fi) Kaivo ja kaivon pohja
FI20095850L (fi) Rakennelma ja menetelmä rakennelman valmistamiseksi, sekä rakennelman käyttö